{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:03:25Z","timestamp":1789995805882,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41669-026-00667-6","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:17:53Z","timestamp":1782901073000},"page":"859-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain"],"prefix":"10.1007","volume":"10","author":[{"given":"Elena","family":"Villama\u00f1an","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Quirce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Covadonga","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00e9stor","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1366-1418","authenticated-orcid":false,"given":"Carla","family":"Gar\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Vidal-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Almonacid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"667_CR1","unstructured":"Gu\u00eda Espa\u00f1ola para el manejo del asma 5.5. https:\/\/neumoped.org\/guia-gema-5-5\/. Accessed July 2025."},{"issue":"6","key":"667_CR2","first-page":"466","volume":"21","author":"S Quirce","year":"2011","unstructured":"Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain. J Investig Allergol Clin Immunol. 2011;21(6):466\u201371.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"667_CR3","doi-asserted-by":"publisher","first-page":"A27","DOI":"10.1016\/j.chest.2020.08.067","volume":"158","author":"A Khan","year":"2018","unstructured":"Khan A, Sternbach N, Kamat S, Annunziata K, Jaffe D, Gouia I. Prevalence of asthma in france, Germany, Italy, Spain, and the United Kingdom, based on the 2018 European National Health and Wellness Survey. Chest. 2018;158(4):A27.","journal-title":"Chest"},{"key":"667_CR4","unstructured":"Ficha t\u00e9cnica Tezspire. https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/1221677001\/FT_1221677001.html.pdf Accessed July 2025."},{"key":"667_CR5","unstructured":"Ficha t\u00e9cnica Xolair. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160909135675\/anx_135675_es.pdf Accessed July 2025."},{"issue":"19","key":"667_CR6","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","volume":"384","author":"A Menzies-Gow","year":"2021","unstructured":"Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"667_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14728222.2020.1783242","volume":"24","author":"GM Gauvreau","year":"2020","unstructured":"Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777\u201392.","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"667_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1056\/NEJMoa1704064","volume":"377","author":"J Corren","year":"2017","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936\u201346.","journal-title":"N Engl J Med"},{"key":"667_CR9","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Producto Sanitario (AEMPS). Available at: https:\/\/cima.aemps.es\/cima\/publico\/lista.html#"},{"issue":"1","key":"667_CR10","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1080\/13696998.2023.2234235","volume":"26","author":"M Habash","year":"2023","unstructured":"Habash M, Guiang H, Mayers I, Quinton A, Vuong V, Dineen A, et al. Cost-effectiveness of tezepelumab in Canada for severe asthma. J Med Econ. 2023;26(1):902\u201314.","journal-title":"J Med Econ"},{"key":"667_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Tezepelumab for treating severe asthma. https:\/\/www.nice.org.uk\/guidance\/ta880\/chapter\/3-Committee-discussion#conclusion."},{"issue":"1","key":"667_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health."},{"issue":"8","key":"667_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/02770903.2018.1499035","volume":"56","author":"C Melero Moreno","year":"2019","unstructured":"Melero Moreno C, Quirce S, Huerta A, Ur\u00eda E, Cuesta M. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. 2019;56(8):861\u201371.","journal-title":"J Asthma"},{"key":"667_CR14","unstructured":"CADTH. Tezepelumab (Tezspire): CADTH Reimbursement Review: Therapeutic area: Asthma.[Internt]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK601779\/table\/tr8269861151140731_ch01_t27\/."},{"key":"667_CR15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4321\/S1135-57272015000600002","volume":"89","author":"B Garc\u00eda-Lorenzo","year":"2015","unstructured":"Garc\u00eda-Lorenzo B, Vallejo-Torres L, Trujillo-Mart\u00edn MdM, Perestelo-P\u00e9rez L, Valc\u00e1rcel-Nazco C, Serrano Aguilar P. Evaluaci\u00f3n econ\u00f3mica busca umbral para apoyar la toma de decisiones. Rev Esp Salud Publica. 2015;89:537\u201344.","journal-title":"Rev Esp Salud Publica"},{"key":"667_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmed.2019.03.006","volume":"151","author":"L P\u00e9rez de Llano","year":"2019","unstructured":"P\u00e9rez de Llano L, Mart\u00ednez-Morag\u00f3n E, Plaza Moral V, Trisan Alonso A, S\u00e1nchez CA, Callejas FJ, et al. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. Respir Med. 2019;151:49\u201354.","journal-title":"Respir Med"},{"issue":"7","key":"667_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650\u201360.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"667_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","volume":"25","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Jason S, Sumeet S, Wilma E, Jennifer R, Pallavi R, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679\u201390.","journal-title":"J Med Econ"},{"issue":"10","key":"667_CR19","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1016\/j.jaip.2020.06.055","volume":"8","author":"R Zeiger","year":"2020","unstructured":"Zeiger R, Sullivan P, Chung Y, Kreindler JL, Zimmerman NM, Tkacz J. Systemic corticosteroid-related complications and costs in adults with persistent asthma. J Allergy Clin Immunol Pract. 2020;8(10):3455-65.e13.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"667_CR20","unstructured":"National Institute for Health and Care Excellence (NICE). Benralizumab for treating severe eosinophilic asthma. Technology appraisal guidance [TA565]. 2019. Available at: https:\/\/www.nice.org.uk\/guidance\/ta565\/documents\/committee-papers."},{"issue":"6","key":"667_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800\u20134.","journal-title":"Med Decis Making"},{"key":"667_CR22","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Tablas de mortalidad del INE por a\u00f1o, sexo, edad y funciones. .[Internet]. https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736177004&menu=resultados&idp=1254735573002."},{"key":"667_CR23","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Defunciones por causas (lista reducida) por sexo y grupos de edad. [Internet]. https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=7947."},{"key":"667_CR24","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Bot Plus Web [Internet]. https:\/\/botplusweb.portalfarma.com\/. Accessed July 2025."},{"key":"667_CR25","unstructured":"Gisbert R, Brosa M. Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud [Internet]. Barcelona: Oblikue Consulting, S.L. http:\/\/www.oblikue.com\/bddcostes\/. Accessed July 2025."},{"key":"667_CR26","unstructured":"European Central Bank. Euro foreign exchange reference rates. https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/eurofxref-graph-gbp.es.html."},{"key":"667_CR27","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. [Internet]. https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=R03DX05."},{"issue":"1","key":"667_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40273-024-01441-4","volume":"43","author":"L Vallejo-Torres","year":"2025","unstructured":"Vallejo-Torres L. Estimating the incremental cost per QALY produced by the Spanish NHS: a fixed-effect econometric approach. Pharmacoeconomics. 2025;43(1):109\u201322.","journal-title":"Pharmacoeconomics"},{"key":"667_CR29","unstructured":"Ministerio de Sanidad. Gu\u00eda de Evaluaci\u00f3n Econ\u00f3mica de Medicamentos del Comit\u00e9 Asesor de la Prestaci\u00f3n Farmac\u00e9utica (CAPF). https:\/\/www.sanidad.gob.es\/areas\/farmacia\/comitesAdscritos\/prestacionFarmaceutica\/docs\/20240227_CAPF_Guia_EE_definitiva.pdf."},{"issue":"5","key":"667_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32(5):722\u201332.","journal-title":"Med Decis Making"},{"key":"667_CR31","unstructured":"Ministerio de Sanidad - Profesionales - Actualizaci\u00f3n de deducciones de Medicamentos seg\u00fan Real Decreto Ley 8\/2010. https:\/\/www.sanidad.gob.es\/areas\/farmacia\/infoIndustria\/infoDeducciones\/ley8_2010\/home.htm."},{"key":"667_CR32","unstructured":"Ministerio de Sanidad. Base de Datos Cl\u00ednicos de Atenci\u00f3n Primaria (BDCAP). Available at: https:\/\/pestadistico.inteligenciadegestion.sanidad.gob.es\/publicoSNS\/C\/base-de-datos-de-clinicos-de-atencion-primaria-bdcap\/parametros;."},{"issue":"1","key":"667_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/03007995.2019.1660539","volume":"36","author":"PW Sullivan","year":"2020","unstructured":"Sullivan PW, Qianyi L, Pinar BS, Joseph D, Abhishek K, Ming Y, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36(1):23\u201332.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"667_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3111\/13696998.2012.756398","volume":"16","author":"F van Nooten","year":"2013","unstructured":"van Nooten F, Sean S, Gert-Jan B, Chris T, Martijn G, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342\u20138.","journal-title":"J Med Econ"},{"issue":"1","key":"667_CR35","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/13696998.2021.1941065","volume":"24","author":"FJ Gonz\u00e1lez-Barcala","year":"2021","unstructured":"Gonz\u00e1lez-Barcala FJ, Xavier M-G, Esther M, Andrea G, Shibing Y, Gijs VDW, et al. Cost-effectiveness analysis of anti\u2013IL-5 therapies of severe eosinophilic asthma in Spain. J Med Econ. 2021;24(1):874\u201382.","journal-title":"J Med Econ"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00667-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00667-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00667-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:13:44Z","timestamp":1789992824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00667-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00667-6","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This analysis was sponsored by AstraZeneca Espa\u00f1a S.A. Gar\u00ed C. and Vidal-Vilar N. were employees of Outcomes'10 (a ProductLife Group Company) Spain, who received an honorarium from AstraZeneca Espa\u00f1a S.A. in connection with the development of this manuscript. Medical writing support was provided by Gar\u00ed C. and Vidal-Vilar N. (Outcomes\u201910 Spain) and was funded AstraZeneca Espa\u00f1a S.A. Torres C. was employee of AstraZeneca Espa\u00f1a S.A. Mart\u00ednez N. was an employee of AstraZeneca Espa\u00f1a S.A. during the development of the model adaptation. Villama\u00f1an E., Quirce S., and Almonacid C. have received speaker and advisory honoraria from AstraZeneca Espa\u00f1a S.A.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors made a meaningful contribution to the conception, design, analysis and interpretation of data, and elaboration and critical review of the manuscript, approved the final manuscript, and agreed to assume responsibility for all aspects of the work.","order":2,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data inputs used in the analyses\u2014including clinical efficacy, utility values, and cost parameters\u2014are described in detail in the article and supplementary materials and were obtained from published literature and official Spanish healthcare databases, whenever possible. Any additional datasets generated during the current study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used to support the findings of this study is not publicly available due to the use of sensitive and confidential data. It may be made available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}